Last reviewed · How we verify
NCT05335473
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Phase 1, PHASE2 trial testing Eribulin and Tucidinostat in HR Positive HER2 Negative Advanced Breast Cancer in 87 participants. Status unknown.
1 May 2025
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 87 |
| Start date | 13 May 2022 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Eribulin and Tucidinostat — full drug profile →
Conditions studied
- HR Positive HER2 Negative Advanced Breast Cancer — all drugs for HR Positive HER2 Negative Advanced Breast Cancer →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 75, female only, with HR Positive HER2 Negative Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914 -
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. · · 2024 · cited 36× · PMID 38937652 · DOI 10.1038/s43018-024-00777-2 -
Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.
Lee RS, Sad K, Fawwal DV, Spangle JM. · · 2023 · cited 17× · PMID 37568822 · DOI 10.3390/cancers15154005 -
Histone acetylation modulators in breast cancer.
Yuan X, Rosen JM. · · 2025 · cited 4× · PMID 40165290 · DOI 10.1186/s13058-025-02006-9 -
Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.
Varun D, Haque M, Jackson-Oxley J, Thompson R, et al · · 2025 · cited 1× · PMID 40805121 · DOI 10.3390/cancers17152418
Verify or expand the search:
- PubMed search for NCT05335473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HR Positive HER2 Negative Advanced Breast Cancer
Currently open trials in the same condition.
- NCT07285382 — Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced · Phase 2 · recruiting
- NCT05890287 — A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy · NA · recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05335473 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 6 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05335473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing